China and Pfizer fail to reach Paxlovid public insurance deal
- The antiviral has not been included in a national register that would have brought the cost down to consumers
- Company’s quote was too high, National Health Security Administration says
………………
A temporary agreement with the administration brought that price to hospitals down to 1,890 yuan and inclusion in the register would have reduced it further to about 700 yuan, according to a report in the Economic Observer.
Paxlovid will still be covered by public health insurance until March 31.
Other news report
China says talks to include Paxlovid in its insurance drug list fail
BEIJING, Jan 8 (Reuters) - China will not include Pfizer Inc's (PFE.N)Paxlovid in an update to its list of medicines covered by basic medical insurance schemes as the U.S. firm quoted a high price for the COVID-19 drug, China's Healthcare Security Administration (NHSA) said on Sunday.
…………………
"We will continue to collaborate with the Chinese government and all relevant stakeholders to secure an adequate supply of Paxlovid in China. We remain committed to fulfilling the COVID-19 treatment needs of Chinese patients," Pfizer said in a statement, without elaborating.
The NHSA said Paxlovid would continue to be eligible to be paid for by state medical insurance until the current planned end-date to the temporary measures of March 31.
注：只是神药没有被正式列入全民医保的年度采购单，并不影响该药在中国的销售、使用、和仿制。
